NasdaqGM - Delayed Quote USD
Eton Pharmaceuticals, Inc. (ETON)
At close: October 21 at 4:00 PM EDT
After hours: October 21 at 4:20 PM EDT
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
31,381.00
31,642.00
21,251.00
21,832.00
39.00
Cost of Revenue
12,715.00
10,581.00
6,933.00
2,827.00
436.00
Gross Profit
18,666.00
21,061.00
14,318.00
19,005.00
-397.00
Operating Expense
24,942.00
22,253.00
22,578.00
20,500.00
26,714.00
Operating Income
-6,276.00
-1,192.00
-8,260.00
-1,495.00
-27,111.00
Net Non Operating Interest Income Expense
690.00
503.00
-761.00
-1,006.00
-859.00
Other Income Expense
--
--
--
546.00
--
Pretax Income
-6,386.00
-689.00
-9,021.00
-1,955.00
-27,970.00
Tax Provision
301.00
247.00
--
--
--
Net Income Common Stockholders
-6,687.00
-936.00
-9,021.00
-1,955.00
-27,970.00
Diluted NI Available to Com Stockholders
-6,687.00
-936.00
-9,021.00
-1,955.00
-27,970.00
Basic EPS
-0.26
-0.04
-0.36
-0.08
-1.33
Diluted EPS
-0.26
-0.04
-0.36
-0.08
-1.33
Basic Average Shares
25,750.50
25,645.00
25,146.00
25,207.00
21,010.00
Diluted Average Shares
25,750.50
25,645.00
25,146.00
25,207.00
21,010.00
Total Operating Income as Reported
-6,276.00
-1,192.00
-8,260.00
-1,495.00
-27,111.00
Total Expenses
37,657.00
32,834.00
29,511.00
23,327.00
27,150.00
Net Income from Continuing & Discontinued Operation
-6,687.00
-936.00
-9,021.00
-1,955.00
-27,970.00
Normalized Income
-6,687.00
-936.00
-9,021.00
-2,501.00
-27,970.00
Net Interest Income
690.00
503.00
-761.00
-1,006.00
-859.00
EBIT
-7,076.00
-1,192.00
-8,260.00
-1,495.00
-27,111.00
EBITDA
-6,047.00
-291.00
-6,486.00
-1,033.00
-26,460.00
Reconciled Cost of Revenue
12,715.00
10,581.00
6,933.00
2,827.00
436.00
Reconciled Depreciation
1,029.00
901.00
1,774.00
462.00
651.00
Net Income from Continuing Operation Net Minority Interest
-6,687.00
-936.00
-9,021.00
-1,955.00
-27,970.00
Total Unusual Items Excluding Goodwill
--
--
--
546.00
--
Total Unusual Items
--
--
--
546.00
--
Normalized EBITDA
-6,047.00
-291.00
-6,486.00
-1,579.00
-26,460.00
Tax Rate for Calcs
0.00
0.00
--
--
--
12/31/2020 - 11/13/2018
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
HROW Harrow, Inc.
56.42
-1.84%
AQST Aquestive Therapeutics, Inc.
4.9500
-1.59%
DERM Journey Medical Corporation
6.32
+3.27%
IRWD Ironwood Pharmaceuticals, Inc.
4.1900
-4.77%
INDV Indivior PLC
8.27
-3.39%
ITCI Intra-Cellular Therapies, Inc.
76.91
-1.83%
ASRT Assertio Holdings, Inc.
1.1500
-0.86%
SUPN Supernus Pharmaceuticals, Inc.
33.67
-2.52%
BFRI Biofrontera Inc.
0.9427
+12.23%
TXMD TherapeuticsMD, Inc.
1.5750
-3.96%